Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions

Karen R Jonscher; Kimberley D Bruce

doi:10.1007/978-3-030-12668-1_3

Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions

Adv Exp Med Biol. 2019:1134:33-58. doi: 10.1007/978-3-030-12668-1_3.

Authors

Karen R Jonscher¹, Kimberley D Bruce²

Affiliations

¹ Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
² Division of Endocrinology, Metabolism, & Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. kimberley.bruce@ucdenver.edu.

PMID: 30919331
DOI: 10.1007/978-3-030-12668-1_3

Abstract

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disorders ranging from simple steatosis to steatosis with inflammation and fibrosis. NAFLD is currently the most prevalent chronic liver disease worldwide, with a global prevalence of 25%, and is soon projected to be the leading cause for liver transplantation in the US. Alarmingly, few effective pharmacotherapeutic approaches are currently available to block or attenuate development and progression of NAFLD. Preclinical models are critical for unraveling the complex and multi-factorial etiology of NAFLD and for testing potential therapeutics. Here we review preclinical models that have been instrumental in highlighting molecular and cellular mechanisms underlying the pathogenesis of NAFLD and in facilitating early proof-of-concept investigations into novel intervention strategies.

Keywords: Intervention strategies; Liver; NAFLD; Non-alcoholic fatty liver disease; Preclinical models; Steatosis.

Publication types

Review

MeSH terms

Disease Progression
Fibrosis
Humans
Inflammation
Liver Transplantation
Non-alcoholic Fatty Liver Disease / diagnosis*
Non-alcoholic Fatty Liver Disease / therapy*

Grants and funding

K25 DK098615/DK/NIDDK NIH HHS/United States